COPPER, 2 x 50 mL

Description

 

PRINCIPLE

In acid solution (pH 4.7), copper (II) is released from the ceruloplasmin protein and reduced to copper (I). The cuprous ion reacts with the 3,5 dibromo-2-pyridylazo-N-ethyl-N (-3-sulfopropyl) -aniline (3,5-diBr-PAESA), and forms a stable coloured complex, which is photometrically measured at 582 nm.

The colour intensity is directly proportional to the concentration of copper ions present in the sample.

DIAGNOSTIC USE

Serum copper levels increase in hemochromatosis, biliary cirrhosis, leukemia, Hodgkins disease, anemia, rheumatoid arthritis, hypothyroidism, malignancy, collagen disease, among others.

The serum copper decreases in Wilsons disease, Menkes syndrome, nephrotic syndrome and burns.

The determination of levels of copper in the urine is used in the study of Wilsons disease (hepatolenticular degeneration).

A single test result could not be used to make a clinical diagnosis. It should integrate clinical and laboratory data.

Technical Inserts